Biotek-snakken — Maj 2021
-
Webcast her kl. 10:00 (hvis det har interesse) https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20210518_1
-
Bemcentinib has the potential to increase the rate of ventilator free survival in more than 50%. VFS observed in 90% in bemcentinib treated patients vs 72% in SOC. Survival benefit and well tolerated. Discussions with gov. and regulators - and Godfrey expect BB to conduct a small confirmation study.
-
Investorevent d. 18/5-2021 med Nordnet, ProInvestor og HC Andersen Capital
Bavarian Nordic 0.11 inde i udsendelsen.
Zealand Pharma 0.44
Genmab 1.20Opsamling med Per Hansen (Nordnet), Helge Larsen (ProInvestor) og Frank Hørning Andersen (HC Andersen Capital): https://www.proinvestor.com/index.php?p=debat_1&postid=93636
-
-
Sarepta Therapeutics presenterar tillsammans med schweiziska Roche data från de första 11 patienterna i Endeavor-studien med genterapikandidaten SRP-9001.
Det framgår av ett pressmeddelande.
Resultaten visar på ett stabilt uttryck av proteinet mikrodystrofin utan att visa några nya säkerhetsrisker. Brist på proteinet leder till muskelförtvining. Studien utvärderar barn med den ovanliga sjukdomen Duchennes muskeldystrofi.
Hansa Biopharmas läkemedel imfilidase används i samband med behandlingen
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S - ORPH
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S - ORPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH). Such investors are...
(www.prnewswire.com)
-
-
Til gengæld er jeg lidt træt af partial clinical hold på MYOV (som jeg fik fisket af i dybet) - ser ud til at vi skal en tur ned igen
https://www.marketwatch.com/story/myovants-stock-falls-after-fda-puts-partial-clinical-hold-on-trial-for-contraceptive-candidate-2021-05-19?siteid=yhoof2 -
Det bliver også spændende, når embargo løftes for Sutros STRO-002 abstract. For de interesserede kan det findes her: https://meetinglibrary.asco.org/results/Sutro Biopharma . Data bliver tilgængelige kl. 23 aften, så vidt jeg kan finde frem til
-
Sutros ny STRO-002 data er opsummeret i denne opdaterede corporate presentation: https://www.sutrobio.com/corporate-presentation/
-
Egentlig synes jeg, at det ser fornuftigt ud. Desværre ingen nye responses blandt de tilbageværende, men samlet mPFS på 7.2 måneder - til sammenligning havde ImmunoGen 4.8 måneder i deres P3 forsøg i langt mindre behandlede patienter. https://investor.immunogen.com/news-releases/news-release-details/immunogen-presents-full-data-phase-3-forward-i-study
Eks. har Chiasma 6-7 af de der standard-søgsmål i forbindelse med sammenlægning med AMYT, og jeg ser det på en række af de US biotek jeg følger 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind